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Effective chemotherapy of tuberculosis requires rapid assessment of drug sensitivity because
of the emergence of multidrug-resistant Mycobacterium tuberculosis. Drug susceptibility
was assessed by a simple method based on the efficient production of photons by viable
mycobacteria infected with specific reporter phages expressing the firefly luciferase gene.
Light production was dependent on phage infection, expression of the luciferase gene, and
the level of cellular adenosine triphosphate. Signals could be detected within minutes after
infection of virulent M. tuberculosis with reporter phages. Culture of conventional strains
with antituberculosis drugs, including isoniazid or rifampicin, resulted in extinction of light
production. In contrast, light signals after luciferase reporter phage infection of drug-resistant
strains continued to be produced. Luciferase reporter phages may help to reduce the time
required for establishing antibiotic sensitivity of M. tuberculosis strains from weeks to days
and to accelerate screening for new antituberculosis drugs.
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uberculosis remains the largest
cause of death in the world from
a single infectious disease (1) and accounts for as much as 40% of deaths in
human immunodeficiency virus (HIV)coinfected individuals in some developing countries (2). Infection with conventional M. tuberculosis can effectively be
cured with a combination of antituberculosis drugs. Ominously, multidrug-resistant tuberculosis (MDR-TB) strains have
emerged in several countries, with case
fatalities ranging from 40 to 60% in immunocompetent individuals and >80%
in immunocompromised individuals (3).
However, because M. tuberculosis has a
doubling time of 20 to 24 hours, current
methodology does not allow determination of drug susceptibility for 2 to 18
weeks (4, 5), leaving patients, contacts,
and health care workers at risk.
Firefly luciferase represents one

of the most efficient available biological reporter molecules because it catalyzes the reaction of luciferin with adenosine triphosphate (ATP) to generate
photons with a quantum yield of 0.85
photons per molecule of substrate reacted (6). Because of the availability of a
variety of sensitive light-detection systems, luciferase has become the standard
assay for measuring ATP (7). Since the
molecular cloning of its cDNA (8), the
firefly luciferase gene has been used directly as a molecular reporter in cells of
a variety of animal, plant, and bacterial
species (9). We reasoned that the expression of luciferase activity could serve as
a sensitive in vivo measure of ATP in
mycobacteria and thus allow us to rapidly test cellular viability of M. tuberculosis after its exposure to different antimycobacterial agents. The optimal use
the gene could be realized if the lucifer819
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ase activity could be measured directly,
without the need for lysing of the mycobacterial cells. To ascertain whether the
substrate, luciferin, could be transported
across the intact mycobacterial cell wall,
we cloned the firefly luciferase (FFlux)
gene downstream of the heat shock protein 60 (hsp60) promoter in a mycobacterial extrachromosomal plasmid vector
(10) and downstream of the gene 71 promoter of mycobacteriophage L5 (11) in
a mycobacterial integrating vector (12)
(Fig. 1A). Both luciferase constructs
were electroporated into Mycobacterium
smegmatis (which multiplies ten times
faster than M. tuberculosis), and luciferase activity was measured in cells grown
to logarithmic phase. On addition of

Figure 1. (A) Expression of firefly luciferase in
mycobacteria. Schematic of the extrachromosomal plasmid pYUB180 and the integration plasmid
pGS16. Abbreviations are as follows: Phsp60, promoter of the BCG hsp60 gene; P71, promoters of
the mycobacteriophage L5’s gene 71; FFlux, firefly luciferase gene; aph, aminoglycoside phosphotransferase that confers kanamycin resistance;
oriE, ColE1 origin of replication; oriM, mycobacterial plasmid pAL5000 origin of replication; attP and
int, L5 integration genes; and bla, β-lactamase that
confers ampicillin resistance to E. coli. (B) Sensitivity of M. smegmatis cells expressing luciferase.
Plasmids pYUB180 and pGSI6 were electroporated into the M. smegmatis strain mc2155 (17). Kanamycin-resistant transformants were grown to a
density of approximately 5 x 108 cells per milliliter,
and tenfold serial dilutions were prepared. Samples (100 μl) were mixed with 250 μI of 0.1 M sodium citrate (pH 5) in a 13 by 75 mm polystyrene
tube. This mixture was placed in the luminometer
(Monolight 2010; Analytical Luminescence Laboratory, San Diego, California), 100 μI of 1 mM luciferin (Sigma, St. Louis, Missouri) was injected
into the tube, and the luciferase activity was measured. Mycobacterium smegmatis cultures are indicated as follows: mc2155 (pYUB180), black;
mc2155 (pGS16), diagonal; and mc2155 cells
alone, white.
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Figure 2. Infection of mycobacteria with LRPs
results in the production of light. (A) Schematic of the luciferase reporter mycobacteriophages
phAE39 and phAE40. Luciferase reporter phages were made by construction of shuttle phasmids
in which an E. coli cosmid pYUB216 (18) was inserted into a nonessential region of the mycobacteriophage TM4. The cosmid pYUB216 contains
(i) FFlux in a transcriptional fusion with the hsp60
promoter of BCG, (ii) a ColE1 origin and an ampicillin resistance gene (Ap) for replication and selection in E. coli, (iii) a bacteriophage λ cos sequence, and (iv) a unique Bcl I site. The phAE39
shuttle phasmid was constructed in a manner similar to that described previously (14), with Bcl Idigested pYUB216 ligated to TM4 DNA that had
been partially digested by SAU 3Al. The resulting shuttle phasmid, phAE39, like its parent TM4,
readily forms plaques of M. tuberculosis, but does
not efficiently form plaques on BCG. Spontaneous host range mutants of phAE39 could be isolated at frequencies of 10–6 to 10–7, and one such
mutant was isolated and designated phAE40.
(B) Light production in mycobacteria after infection with the luciferase reporter phage phAE40. High titers of phAE40 were prepared as described previously for TM4 phages (19). Mycobacterium smegmatis, mc2155 cells, and BCG-Pasteur cells were grown in roller bottles to approximately 5 × 107 cells per
milliliter in Middlebrook 7H9 broth with ADC enrichment and 0.05% Tween-80 [M-ADC-TW broth (19)] at
37°C. Either the M. smegmatis or the BCG cells were harvested by centrifugation and washed twice in
M-ADC broth (containing no Tween-80). The resulting pellet was resuspended in the original volume of
M-ADC broth. The cells were diluted fivefold into fresh M-ADC broth and were allowed to incubate overnight standing at 37°C. (Tween-80 seems to remove the receptors, and we have found that optimal activities are attained if the cells have a chance to grow in the absence of Tween-80. This procedure possibly
allows regeneration of phage receptors.) One milliliter of washed cells (approximately 5 × 107 cells) was
mixed with 0.1 ml of phAE40 particles [5 × 108 plaque-forming units (PFU) per milliliter] that had been
concentrated on CsCl gradients to attain a multiplicity of infection of 10. The cell-phage mixture was incubated at 37°C. Beginning at the time of the addition of the phAE40, we removed 0.1-ml samples at the
times designated in the graph. Luciferase activity was measured as described in Figure 1 and plotted.
Filled circles, BCG cells alone; open circles, BCG cells plus phAE40; filled triangles, mc2155 cells alone;
filled squares, mc2155 cells plus phAE40; open squares, phAE40 alone.

Figure 3. Comparison of the kinetics of light production of
drug-sensitive BCG cells to that of drug-resistant BCG mutant cells after phage infection. Spontaneous mutants of
BCG-Pasteur strains were isolated on Middlebrook 7H10
agar containing either rifampicin (50 μg/ml), streptomycin
(250 μg/ml), or isoniazid (5 μg/ml). The rifampicin-, streptomycin-, or isoniazid-resistant mutants were purified and
designated as mc2768, mc2767, and mc2765, respectively.
All three mutants and the BCG parent were grown to midlogarithmic phase, harvested, and washed as described
in Figure 2 BCG cells (circles) and mutant cells (squares)
were incubated in the presence (open symbols) or absence (filled symbols) of rifampicin, streptomycin, or isoniazid. (A) The mc2768 cells and the BCG cells were incubated standing at 37°C in the presence or absence of
rifampicin (50 μg/ml) for 24 hours. A 0.5-ml sample (approximately 5 × 107 viable cells) was mixed with 0.1 ml
(5 × 108 PFU) of phAE40 particles, and luciferase activity
was determined as described in Figure 2 and plotted as a
representative experiment. This experiment was repeated
a minimum of three times. The absolute background and
peak luminescence signals varied approximately twofold
between experiments, but the ratios of signals of drug-resistant relative to susceptible cells were constant (20- to
100-fold depending on the strain). (B) The mc2767 cells
and the BCG cells were incubated standing at 37°C in the
presence or absence of streptomycin (250 μg/ml) for 24
hours. (C) The mc2765 cells and the BCG cells were incubated standing at 37°C in the presence or absence of isoniazid (50 μg/ml) for 24 hours.
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Figure 4. Use of luciferase reporter phage assay
to distinguish drug-sensitive from drug-resistant M.
tuberculosis strains. The following M. tuberculosis
strains were grown in a biological safety level 3 containment facility: (i) The virulent drug-sensitive M. tuberculosis Erdman strain; (ii) strain 92-2025, a singly
isoniazid-resistant strain; and (iii) an MDR strain of
tuberculosis that has been shown to be resistant to
rifampicin, streptomycin, isoniazid, ethambutol, and
ethionamide and the cause of several nosocomial
outbreaks in New York City (20). The Erdman strain
was subcultured from the starter culture by inoculation of 0.4 ml into 20 ml of Middlebrook 7H9 broth
containing OADC enrichment (Difco Laboratories,
Detroit, Michigan) plus 0.5 Tween-80 (M-OADCTW broth). The 92-2025 and the MDR strains, which
grow more slowly than the Erdman strain, were subcultured by inoculation of 2 ml into 20 ml M-OADCTW broth. All three cultures were grown standing
at 37°C for 7 to 8 days. The cells were washed as
described above and 0.5. resuspended in 0.5× the
original volume. Washed cells (0.2 ml) were inoculated into 0.7 ml of M-OADC broth (19) and incubated in 13 by 100 mm polypropylene tubes in a heating block in a biohazard hood for 48 hours. Rifampicin, streptomycin, or isoniazid were added to final
concentrations of 2 μg/ml, 6 μg/ml, and 1 μg/ml, respectively. After 48 hours of incubation, 0.1 ml of
phAE40 particles (1 × 1011 particles) were added to attain a multiplicity of infection of 1000. Samples of
100 μI were removed at 1, 3, and 5 hours after addition of the phage and were mixed with 250 μI of 0.1
M sodium citrate (pH 5) in a Lumacuvette (Lumac BV, Netherlands). One hundred microliters of 1 mM luciferin were added, and the Lumacuvette was plugged with cotton. The tube was placed in a Lumac Biocounter (M1500 P), and readings were recorded as described above. (The Lumac biocounter has dimensions that permit it to fit in a standard biohazard hood.) The light production followed kinetics similar to
the BCG experiments, and the readings at 3 and 5 hours differed by no more than twofold. The results at
3 hours are shown for the Erdman (A), 92-2025 (B), and the MDR (C) M. tuberculosis strains. A repeated experiment gave similar results, with the samples cultured in the absence of drug exhibiting an 80-fold
greater luminescence than the cells cultured with rifampicin or streptomycin and greater than tenfold luminescence relative to those cultured with isoniazid at 3 and 5 hours. Open bars, cells alone; filled bars,
cells plus LRPs; diagonal lines, cells plus rifampicin plus LRPs; cross-hatching, cells plus streptomycin
plus LRPs; squares, cells plus isoniazid plus LPRs.

luciferin, luciferase activity was readily measured from intact mycobacterial cells infected with both the extrachromosomal and the integrating vectors
(Fig. 1B). Serial dilutions indicated that
it was possible to detect as few as 500 to
5000 M. smegmatis cells expressing firefly luciferase (Fig. 1B), establishing that
the luciferase-luciferin system could be
developed as a sensitive reporter system
for ATP in mycobacteria.
The ability to make use of the luciferase reporter gene to assess drug susceptibilities in clinical isolates requires an
efficient means for delivering the luciferase gene into the M. tuberculosis cells.
Phages offer an ideal vehicle with which
to deliver a foreign gene to every cell in
a bacterial culture (13). We have previously developed shuttle phasmid vectors
from a variety of mycobacteriophages
that can be genetically manipulated in
Escherichia coli and then used to deliver
the recombinant DNA into mycobacteria
by infection with high efficiency (14).
A shuttle phasmid, phAE39, was constructed from mycobacteriophage TM4,
which forms plaques on both the fastgrowing mycobacterium M. smegmatis

and the slow-growing mycobacterium
M. tuberculosis, by insertion of an E.
coli cosmid into which the FFlux gene
had been inserted downstream of the
strong hsp60 promoter (Fig. 2A). A host
range mutant of phAE39, phAE40, was
isolated that was capable of infecting bacillus Calmette-Guerin (BCG) vaccine
strains, in addition to M. smegmatis and
M. tuberculosis (Fig. 2A). To test whether these resulting luciferase reporter
phages (LRPs) could elicit the production of light after infection of mycobacteria, we mixed the LRPs with M. smegmatis cells and then exposed the mixture
at different times to luciferin. Light signals could be detected by means of a
luminometer within minutes of infection and increased 1000-fold within 2
hours (Fig. 2B). The signals are two to
three orders of magnitude lower than an
equivalent number of cells harboring the
luciferase plasmids, probably as a result
of less efficient gene expression or of inhibitory effects of the phage on host cell
metabolism or ATP levels. The similarity
of the kinetics of light production in M.
smegmatis and BCG (Fig. 2B) suggests
that differences in gene expression may
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not be the principal determinant in the
tenfold slower growth of BCG (or M. tuberculosis) relative to M. smegmatis.
It then became feasible to test whether the luciferase reporter phages were
capable of distinguishing drug-resistant
from drug-susceptible organisms. Mutants of BCG were selected that were resistant to rifampicin, streptomycin, or
isoniazid (Fig. 3). When wild-type BCG
and the mutants were cultured for 24
hours with the antibiotics, the parental
strain did not produce any signal, whereas light was produced by the drug-resistant mutants (Fig. 3). Finally, the luciferase reporter phage assay was tested on
clinically derived M. tuberculosis strains,
both singly and multiply drug-resistant
(MDR). The results (Fig. 4) established
that luciferase reporter phages can rapidly reveal the patterns of drug susceptibility or resistance of M. tuberculosis
strains. The apparent lower activity of
M. tuberculosis relative to BCG (Fig. 3)
primarily reflects the use of a luminometer with different light unit definition and
sensitivity rather than an intrinsic difference between bacterial strains (15).
Because of the emergence of multidrug-resistant strains, it has become increasingly important to rapidly ascertain
patterns of drug susceptibility. These observations demonstrate the use of luciferase reporter mycobacteriophages as simple tools for the rapid determination of
drug susceptibility profiles of M. tuberculosis. It is expected that this methodology will be adapted for use on clinical
isolates with a minimum time of culture.
This might be achieved by an increase
in the sensitivity of the assay or by engineering of better characterized mycobacteriophages, such as L5 [whose complete DNA sequence is known (16)], to
permit higher expression of luciferase.
The technology could be adapted for use
in developing countries either through
use of inexpensive luminometers or of
sensitive film technology (7). In addition, luciferase phages or M. tuberculosis strains expressing luciferase genes
may permit rapid screening of drugs for
antituberculosis activity.
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